2. Immunology/Inflammation
  3. NOD-like Receptor (NLR) Interleukin Related
  4. Maresin 2

Maresin 2 is an anti-inflammatory and pro-resolving mediator. Maresin 2 drives intestinal epithelial cell migration by activating the focal cell-matrix adhesion signaling pathway in primary human intestinal epithelial cells, thereby promoting mucosal wound repair. Maresin 2 alleviates nociceptive and anxiety-like behaviors in rats with type 1 diabetes by inhibiting IL-1β in the spinal cord and prefrontal cortex. Maresin 2 attenuates allergic airway inflammation in mice by inhibiting the activation of the NLRP3 inflammasome, Th2-type immune responses, and oxidative stress. Maresin 2 inhibits inflammatory and neuropathic trigeminal neuralgia and reduces neuronal activation in the trigeminal ganglion. Maresin 2 promotes inflammation resolution and mucosal repair after DSS-induced colitis or biopsy-induced colonic mucosal injury.

For research use only. We do not sell to patients.

Maresin 2

Maresin 2 Chemical Structure

CAS No. : 1639809-46-3

Size Price Stock Quantity
Solvent
10 μg (277.4 μM * 100 μL in Ethanol) In-stock

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

Other Forms of Maresin 2:

Maresin 2 Related Antibodies

Top Publications Citing Use of Products

View All NOD-like Receptor (NLR) Isoform Specific Products:

View All Isoforms
NLRP3 NLRP1 NOD1 NOD2

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Maresin 2 is an anti-inflammatory and pro-resolving mediator. Maresin 2 drives intestinal epithelial cell migration by activating the focal cell-matrix adhesion signaling pathway in primary human intestinal epithelial cells, thereby promoting mucosal wound repair. Maresin 2 alleviates nociceptive and anxiety-like behaviors in rats with type 1 diabetes by inhibiting IL-1β in the spinal cord and prefrontal cortex. Maresin 2 attenuates allergic airway inflammation in mice by inhibiting the activation of the NLRP3 inflammasome, Th2-type immune responses, and oxidative stress. Maresin 2 inhibits inflammatory and neuropathic trigeminal neuralgia and reduces neuronal activation in the trigeminal ganglion. Maresin 2 promotes inflammation resolution and mucosal repair after DSS-induced colitis or biopsy-induced colonic mucosal injury[1][2][3][4][5].

IC50 & Target[1]

NLRP3 inflammasome

 

IL-1β

 

In Vitro

Maresin 2 (200 nM; 16-24 h) enhances scratch wound closure and migration efficiency in HT29/B6 human intestinal epithelial cells when combined with 10 ng/mL TNFα/IFNγ, but has no effect on unstimulated cells[1].
Maresin 2 (200 nM; 16 h) activates the FAK-Src-paxillin and talin-vinculin focal adhesion signaling axes in HT29/B6 human intestinal epithelial cells when combined with 10 ng/mL TNFα/IFNγ, promoting pro-migration signaling at wound leading edges[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Maresin 2 Related Antibodies

Immunofluorescence[1]

Cell Line: HT29/B6 human intestinal epithelial cells
Concentration: 200 nM
Incubation Time: 16 h
Result: Increased numbers of vinculin-containing focal adhesions at the leading edge of spreading cells significantly relative to TNFα/IFNγ alone (P < 0.01).
In Vivo

Maresin 2 (2 ng/g body weight; intraperitoneal injection; single dose; 24 h post-trauma) significantly increases the colonic mucosal wound healing rate to 47.67% at 72 h post-injury in a biopsy-induced colonic mucosal injury model of C57BL/6 mice[1].
Maresin 2 (2 ng/g body weight; intraperitoneal injection; administered on days 0, 2, 4, 6, and 8 for a total of 5 times) significantly reduces disease activity and colonic mucosal injury in the 5% DSS-induced colitis model of C57BL/6 mice, with a histological colitis score of 3.951[1].
Maresin 2 (1-10 ng per rat; i.p.; administered daily for 2 consecutive days followed by every other day; on days 14-32 after streptozotocin induction) significantly alleviates mechanical hyperalgesia in streptozotocin-induced male Wistar diabetic rats (at doses of 1, 3 and 10 ng/rat), improves anxiety-like behavior at a dose of 3 ng/rat, and normalizes IL-1β levels in the spinal cord and prefrontal cortex[2].
Maresin 2 (1 ng per mouse; intravenous injection; for 4 consecutive days) exerts a protective effect on ovalbumin-induced asthma in female BALB/c mice, and alleviates airway inflammation, Th2 immune response, NLRP3 inflammasome activation and oxidative stress[3].
Maresin 2 (1-10 ng; intrathecal; single injection) significantly attenuates the acute and inflammatory phases of formalin-induced orofacial nociception in rats[5].
Maresin 2 (10 ng; administered twice on postoperative day 1 and day 3) prevents the development of thermal hyperalgesia and mechanical hyperalgesia in a rat model of postoperative orofacial pain[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 (10 to 12 weeks old, male and female, biopsy-induced colonic mucosal injury)[1]
Dosage: 2 ng/g body weight
Administration: i.p.; single injection; 24 h post-wounding
Result: Increased colonic mucosal wound healing to 47.67% at 72 h post-wounding compared to 34.58% in vehicle control mice (P < 0.01).
Animal Model: C57BL/6 (10 to 12 weeks old, male and female, 5% DSS-induced colitis)[1]
Dosage: 2 ng/g body weight
Administration: i.p.; 5 doses on days 0, 2, 4, 6, and 8
Result: Reduced disease activity index (DAI) scores at multiple time points (P < 0.01, P < 0.001, P < 0.0001).
Reduced histological colitis score to 3.951 compared to 5.474 in vehicle control mice (P < 0.05).
Decreased mucosal ulceration/erosion and infiltrating immune cells.
Animal Model: Wistar rats (male, 180-240 g, streptozotocin-induced type 1 diabetes mellitus)[2]
Dosage: 1 ng/rat; 3 ng/rat; 10 ng/rat
Administration: i.p.; daily for 2 consecutive days, then alternate days; days 14-32 post-streptozotocin induction
Result: Failed to alter mechanical threshold in diabetic rats after acute treatment.
Showed significant improvement in mechanical threshold at 3 ng dose on day 20 post-streptozotocin induction (p = 0.0017).
Showed significant improvement in mechanical threshold at all doses (1, 3, 10 ng) on day 26 post-streptozotocin induction (p < 0.05) compared to vehicle-treated diabetic rats.
Significantly increased time spent in open arms (p = 0.05) and decreased time spent in closed arms (p < 0.05) in elevated plus-maze test at 3 ng dose compared to vehicle-treated diabetic rats.
Did not alter depressive-like behavior in modified forced swimming test or locomotor/exploratory behavior in open-field test at any dose.
Reversed elevated IL-1β levels in spinal cord at 3 ng (p = 0.0170) and 10 ng (p = 0.0445) doses compared to vehicle-treated diabetic rats.
Reversed elevated IL-1β levels in prefrontal cortex at all doses (1 ng, p = 0.0151; 3 ng, p = 0.0266; 10 ng, p = 0.0201) compared to vehicle-treated diabetic rats.
Did not affect IL-1β levels in hippocampus, hyperglycemia, or low weight gain in diabetic rats at any dose.
Animal Model: BALB/c (female, 6-8 weeks old, 20-25 g, specific pathogen-free, ovalbumin-induced asthma model)[3]
Dosage: 1 ng per mouse
Administration: i.v.; daily; 4 days
Result: Reduced airway inflammation score (P < 0.05) and goblet cell proliferation score (P < 0.05).
Decreased lung tissue expression of MPO (P < 0.01) and Ly-6G (P < 0.05).
Lowered total inflammatory cell count (P < 0.05), neutrophil count (P < 0.05), and eosinophil count (P < 0.05) in BALF.
Reduced BALF levels of Th2 cytokines IL-4 (P < 0.01), IL-5 (P < 0.01), and IL-13 (P < 0.01).
Lowered serum total IgE (P < 0.01) and ovalbumin-specific IgE (P < 0.05).
Decreased lung tissue expression of NLRP3 (P < 0.05), ASC (P < 0.05), and Caspase-1 (P < 0.05).
Reduced BALF levels of IL-1β (P < 0.05) and IL-18 (P < 0.05).
Decreased lung tissue MDA levels (P < 0.05) and increased GSH (P < 0.05) and SOD (P < 0.01) levels.
Reduced lung tissue ICAM-1 expression (P < 0.01).
Molecular Weight

360.49

Formula

C22H32O4
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

CC/C=C\C/C=C\C[C@@H]([C@@H](/C=C/C=C/C=C\C/C=C\CCC(O)=O)O)O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Solution, -20°C, 2 years
Purity & Documentation

Purity: 97.2%

SDS (393 KB)

COA (239 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Maresin 2 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Maresin 21639809-46-3Maresin2Maresin-2NOD-like Receptor (NLR)Interleukin RelatedILsoluble epoxide hydrolaseC57BL/6 micefocal adhesion kinaseNLRP3 inflammasome12-lipoxygenasepaxillintrigeminal ganglion neuronHT29/B6 human intestinal epithelial cellshuman macrophagesSrc kinaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Maresin 2
Cat. No.:
HY-119684
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.